Circular RNA-encoded protein SCAP-129aa drives platinum resistance in triple-negative breast cancer, new study from Sun Yat-Sen University finds
Peer-Reviewed Publication
This month, we're turning our attention to Breast Cancer Awareness Month, a time dedicated to increasing awareness, supporting early detection, and highlighting the ongoing research shaping the future of breast cancer treatment and prevention.
Updates every hour. Last Updated: 23-Dec-2025 09:11 ET (23-Dec-2025 14:11 GMT/UTC)
A team from Sun Yat-sen University Sun Yat-sen Memorial Hospital has identified a novel mechanism underlying platinum resistance in triple-negative breast cancer (TNBC): the circular RNA circSCAP encodes a 129-amino-acid protein (SCAP-129aa) that activates the PI3K/AKT pathway by stabilizing PIK3R2. Silencing circSCAP or combining platinum therapy with the PIK3R2 inhibitor significantly improved treatment efficacy in preclinical models, highlighting circSCAP and SCAP-129aa as potential biomarkers and therapeutic targets.
A University of Cambridge study of adult mammary gland development has revealed new genes involved in breastfeeding, and provided insights into how genetic changes may be associated with breastfeeding disorders and postpartum breast cancers.
Clinical trials show promising results in treating pancreatic and colorectal cancers
New treatment strategies improve outcomes for patients with kidney and testicular cancers
Novel research techniques enable advances in gene-drug interactions, breast cancer progression, and identifying pre-cancerous lesions
Biomarkers help predict risk for oral cancer metastasis